Boehringer Ingelheim announced today that it has launched clinical development of its first-in-class IL-11 inhibitor antibody BI 765423 with a Phase 1 study ( NCT05658107 ) to assess the safety, tolerability, and pharmacokinetics in healthy volunteers.
